Ocugen (OCGN) Net Income towards Common Stockholders (2014 - 2026)
Ocugen posted quarterly Net Income towards Common Stockholders of -$19.2 million for Q1 2026, down 24.93% year-on-year from -$25.5 million in Q1 2025, and up 4.36% on a QoQ basis from -$20.1 million in Q3 2025.
Ocugen (OCGN) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$19.2 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 24.93% year-over-year to -$19.2 million; the trailing twelve-month figure through Mar 2026 stood at -$54.0 million (up 22.14% YoY), and the FY2024 full-year result was -$54.0 million, up 14.38% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$19.2 million, up from -$20.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$11.0 million in Q4 2023 and bottomed at -$54.0 million in Q4 2024.
- The 5-year median for Net Income towards Common Stockholders is -$19.6 million (2025), against an average of -$21.7 million.
- The widest annual swing landed in 2023, when Net Income towards Common Stockholders surged 50.0%; it then sank 391.92% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$21.9 million in 2022, then soared by 50.0% to -$11.0 million in 2023, then tumbled by 391.92% to -$54.0 million in 2024, then jumped by 62.84% to -$20.1 million in 2025, then increased by 4.36% to -$19.2 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$19.2 million (Q1 2026), -$20.1 million (Q3 2025), and -$14.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - | -19.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.18 Mn |
| Sep 30, 2025 | -20.05 Mn |
| Jun 30, 2025 | -14.74 Mn |
| Mar 31, 2025 | -15.35 Mn |
| Dec 31, 2024 | -53.96 Mn |
| Dec 31, 2023 | -10.97 Mn |
| Jun 30, 2023 | -23.07 Mn |
| Mar 31, 2023 | -18.04 Mn |
| Dec 31, 2022 | -21.94 Mn |
| Sep 30, 2022 | -21.92 Mn |
| Jun 30, 2022 | -21.58 Mn |
| Mar 31, 2022 | -19.03 Mn |
| Dec 31, 2021 | -14.58 Mn |
| Sep 30, 2021 | -10.76 Mn |
| Jun 30, 2021 | -25.95 Mn |
| Mar 31, 2021 | -7.08 Mn |
| Dec 31, 2020 | -3.79 Mn |
| Sep 30, 2020 | -10.47 Mn |
| Jun 30, 2020 | -16.16 Mn |
| Mar 31, 2020 | -3.94 Mn |
| Dec 31, 2019 | 12.38 Mn |
| Sep 30, 2019 | -22.77 Mn |
| Jun 30, 2019 | -3.54 Mn |
| Mar 31, 2019 | -9.39 Mn |
| Dec 31, 2018 | -6.40 Mn |
| Sep 30, 2018 | -3.40 Mn |
| Jun 30, 2018 | -3.70 Mn |
| Mar 31, 2018 | -14.37 Mn |
| Dec 31, 2017 | -6.01 Mn |
| Sep 30, 2017 | -5.08 Mn |
| Jun 30, 2017 | -5.45 Mn |
| Mar 31, 2017 | -5.83 Mn |
| Dec 31, 2016 | -7.92 Mn |
| Sep 30, 2016 | -9.23 Mn |
| Jun 30, 2016 | -8.04 Mn |
| Mar 31, 2016 | -7.92 Mn |
| Dec 31, 2015 | -8.34 Mn |
| Sep 30, 2015 | -8.08 Mn |
| Jun 30, 2015 | -7.63 Mn |
| Mar 31, 2015 | -7.96 Mn |
| Dec 31, 2014 | -6.67 Mn |
| Sep 30, 2014 | -11.97 Mn |
| Jun 30, 2014 | -11.82 Mn |
| Mar 31, 2014 | -5.17 Mn |